These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36593103)

  • 1. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
    Fu Y; Mackowiak B; Feng D; Lu H; Guan Y; Lehner T; Pan H; Wang XW; He Y; Gao B
    Gut; 2023 Oct; 72(10):1942-1958. PubMed ID: 36593103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    He L; Xu K; Niu L; Lin L
    Pharm Biol; 2022 Dec; 60(1):1710-1720. PubMed ID: 36086826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability.
    Qiu J; Zhong F; Zhang Z; Pan B; Ye D; Zhang X; Yao Y; Luo Y; Wang X; Tang N
    Int Immunopharmacol; 2024 Jul; 136():112415. PubMed ID: 38850791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
    Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
    Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.
    Fan F; Chen K; Lu X; Li A; Liu C; Wu B
    Hepatol Int; 2021 Apr; 15(2):444-458. PubMed ID: 33219943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
    Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
    Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
    Xiong Z; Chan SL; Zhou J; Vong JSL; Kwong TT; Zeng X; Wu H; Cao J; Tu Y; Feng Y; Yang W; Wong PP; Si-Tou WW; Liu X; Wang J; Tang W; Liang Z; Lu J; Li KM; Low JT; Chan MW; Leung HHW; Chan AWH; To KF; Yip KY; Lo YMD; Sung JJ; Cheng AS
    Gut; 2023 Sep; 72(9):1758-1773. PubMed ID: 37019619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic inflammatory IgA
    Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
    Wang Y; Cao K
    J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.
    Wang Q; Tan W; Zhang Z; Chen Q; Xie Z; Yang L; Tang C; Zhuang H; Wang B; Jiang J; Ma X; Wang W; Hua Y; Shang C; Chen Y
    Apoptosis; 2024 Oct; 29(9-10):1529-1545. PubMed ID: 38824477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
    Lv T; Xiong X; Yan W; Liu M; Xu H; He Q
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
    Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
    Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.